Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations - TROPION-Lung10

Exclusion Criteria

• - Prior systemic therapy for advanced/metastatic NSCLC.
• - Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
• - History of another primary malignancy within 3 years
• - Active or prior documented autoimmune or inflammatory disorders (with exceptions)
• - Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease.
• - Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
• - History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
• - Has significant pulmonary function compromise, as determined by the investigator
• - Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
• - History of leptomeningeal carcinomatosis
• - Known clinically significant corneal disease
• - Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
• - History of active primary immunodeficiency